SEC Form SD filed by British American Tobacco Industries p.l.c.
$BTI
Medicinal Chemicals and Botanical Products
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form SD
SPECIALIZED DISCLOSURE REPORT
BRITISH AMERICAN TOBACCO P.L.C.
(Exact name of the registrant as specified in its charter)
|
England and Wales
|
001-38159
|
98-0207762
|
||
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
||
|
Globe House
4 Temple Place
London WC2R 2PG
United Kingdom
|
||||
|
(Address of principal executive offices)
|
||||
Caroline Ferland, +44 (0)20 7845 1000
(Name and telephone number, including area code, of the person
to contact in connection with this report)
Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
|
☒
|
Rule 13p‑1 under the Securities Exchange Act (17 CFR 240.13p‑1) for the reporting period from January 1 to December 31, 2024.
|
Section 1 - Conflict Minerals Disclosure
Item 1.01 Conflict Minerals Disclosure and Report
A copy of British American Tobacco p.l.c.’s (“BAT”) Conflict Minerals Report is provided as Exhibit 1.01 to this Form SD and is publicly available at www.bat.com/reporting. The information contained in, and that can be accessed through,
either BAT’s website or any website referred to in the Conflict Minerals Report is not, and shall not be deemed to be, a part of this Form SD or incorporated into any other filings BAT makes with the Securities and Exchange Commission.
Item 1.02 Exhibit
A copy of BAT’s Conflict Minerals Report is provided as Exhibit 1.01 to this Form SD.
Section 2 – Resource Extraction Issuer Disclosure
N/A
Section 3 – Exhibits
Item 3.01 Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
| BRITISH AMERICAN TOBACCO P.L.C. | ||||
|
By:
|
/s/ Soraya Benchikh
|
|||
| Name: |
Soraya Benchikh |
|||
| Title: |
Chief Financial Officer |
|||
Date: April 16, 2025